scholarly journals Dominant Negative Function by an Alternatively Spliced Form of the Interferon-inducible Protein Kinase PKR

2001 ◽  
Vol 276 (17) ◽  
pp. 13881-13890 ◽  
Author(s):  
Suiyang Li ◽  
Antonis E. Koromilas
1995 ◽  
Vol 218 (1) ◽  
pp. 17-27 ◽  
Author(s):  
Ian W. Jeffrey ◽  
Suzanne Kadereit ◽  
Eliane F. Meurs ◽  
Thomas Metzger ◽  
Michael Bachmann ◽  
...  

2003 ◽  
Vol 198 (7) ◽  
pp. 1043-1055 ◽  
Author(s):  
Katherine A. Fitzgerald ◽  
Daniel C. Rowe ◽  
Betsy J. Barnes ◽  
Daniel R. Caffrey ◽  
Alberto Visintin ◽  
...  

Toll–IL-1–resistance (TIR) domain–containing adaptor-inducing IFN-β (TRIF)–related adaptor molecule (TRAM) is the fourth TIR domain–containing adaptor protein to be described that participates in Toll receptor signaling. Like TRIF, TRAM activates interferon regulatory factor (IRF)-3, IRF-7, and NF-κB-dependent signaling pathways. Toll-like receptor (TLR)3 and 4 activate these pathways to induce IFN-α/β, regulated on activation, normal T cell expressed and secreted (RANTES), and γ interferon–inducible protein 10 (IP-10) expression independently of the adaptor protein myeloid differentiation factor 88 (MyD88). Dominant negative and siRNA studies performed here demonstrate that TRIF functions downstream of both the TLR3 (dsRNA) and TLR4 (LPS) signaling pathways, whereas the function of TRAM is restricted to the TLR4 pathway. TRAM interacts with TRIF, MyD88 adaptor–like protein (Mal)/TIRAP, and TLR4 but not with TLR3. These studies suggest that TRIF and TRAM both function in LPS-TLR4 signaling to regulate the MyD88-independent pathway during the innate immune response to LPS.


Oncogene ◽  
2001 ◽  
Vol 20 (41) ◽  
pp. 5836-5845 ◽  
Author(s):  
Nadvia Delhem ◽  
Abdelmajid Sabile ◽  
Rodrigo Gajardo ◽  
Philippe Podevin ◽  
Annie Abadie ◽  
...  

Cell ◽  
2002 ◽  
Vol 108 (2) ◽  
pp. 221-232 ◽  
Author(s):  
Yitzhak Ben-Asouli ◽  
Yona Banai ◽  
Yehuda Pel-Or ◽  
Alexei Shir ◽  
Raymond Kaempfer

Sign in / Sign up

Export Citation Format

Share Document